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ABSTRACT 
OBJECTIVE: The objective of this systematic review is to determine whether or not besifloxacin 
ophthalmic suspension 0.6% is safe and effective for the treatment of bacterial conjunctivitis. 
STUDY DESIGN: Review of three trials in the English language, all published in 2009.  
DATA SOURCES: Randomized, double masked, multicenter parallel group studies comparing 
besifloxacin to a vehicle suspension or moxifloxacin were found using Ovid MEDLINE, and 
Cochrane databases. 
OUTCOME MEASURED: Resolution of bacterial conjunctivitis through reduced or eliminated 
signs or symptoms, the microbial eradication of the bacteria responsible for the disease, and the 
safety of the medication used in terms of adverse events while treating bacterial conjunctivitis 
with besifloxacin.  
RESULTS: All three double blinded RCTs demonstrated that besifloxacin was more safe and 
effective in treating bacterial conjunctivitis when compared with a vehicle suspension. When 
besifloxacin was compared with moxifloxacin, it was concluded that besifloxacin is not inferior 
to moxifloxacin for the treatment of bacterial conjunctivitis.  
CONCLUSIONS: The results of the RCTs demonstrate that besifloxacin for the treatment of 
bacterial conjunctivitis is safe and effective. More studies are needed comparing other drug 
treatments, different strengths, the safety and efficacy in children versus adults and the duration 
of the medicine adminitaration. Future studies will help to determine the best medicinal option in 
treating bacterial conjunctivitis safely and effectively.  
KEY WORDS: Besifloxacin, Bacterial Conjunctivitis 
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Introduction 
 Bacterial conjunctivitis, whether acute or chronic is the most common eye disorder that 
nearly everyone will face at least once in their lifetime. Bacterial conjunctivitis is a disease that 
is symptomatically defined by a copious purulent discharge, mild eye discomfort due to sticky 
eyelids, redness and ocular irritation. The most common organisms to cause bacterial 
conjunctivitis are Staphylococci, Streptococci, Haemophilus, Pseudomonas, and Moraxella. In 
many cases, bacterial conjunctivitis is obtained from upper respiratory infections that have 
spread to the eye, although there are other ways of transmitting the disease. Many bacterial 
conjunctivitis cases are also due to transmission from an infected person to another through 
infected areas and close personal contact. Moreover, conjunctivitis can also exist due to viruses. 
Viral conjunctivitis is distinguished from bacterial conjunctivitis due to its characteristic clear 
discharge.
1
 
 This eye disease is of great importance to primary care patients due to the high 
prevalence of the disease. Due to its ability to affect anyone in all age groups, bacterial 
conjunctivitis is important to treat and prevent. Although it is a self limiting disease in most 
cases, the use of antibiotics for its treatment has ultimately led to reduced transmission, quicker 
recovery time, shorter duration of the disease and reduced complications from long standing 
disease.
2 
Prevention of bacterial conjunctivitis is also possible through management of associated 
diseases such as acute otitis media and bacterial pneumonia, which can result in bacterial 
conjunctivitis if untreated.
1 
 
Currently, methods that are used to treat bacterial conjunctivitis include topical 
antibiotics such as sulfacetamide 10%, polymixin-bacitracin-neomycin, and trimethoprim-
polymixin. Broad spectrum topical antibiotics are sufficient to treat the disease and cultures of 
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the ocular discharge are done to determine antibiotic resistance or in cases refractory to 
medicinal treatment. The total direct and indirect cost of treating bacterial conjunctivitis in the 
United States in 2005 was estimated to be $589 million.
2
 Costs include primary care visits and 
the cost of medicinal treatment, primarily topical broad spectrum antibiotics.  
 Besifloxacin is another topical antibiotic that can be used as an option to treat those who 
have been affected by bacterial conjunctivitis. Besifloxaxin is a fluoroquinolone that has fairly 
good broad spectrum antibiotic activity. It is an FDA approved drug for the treatment of bacterial 
conjunctivitis, that has shown success in treating bacterial conjunctivitis as well as preventing 
complications and reducing transmission as well as duration of the disease.  
Objective 
 The goal of this review is to determine whether or not besifloxacin ophthalmic 
suspension 0.6% is safe and effective for the treatment of bacterial conjunctivitis. Previous 
randomized controlled trials that have been published on besifloxacin ophthalmic suspension 
0.6% for the treatment of bacterial conjunctivitis have shown that besifloxaxin is a safe and 
effective treatment and can be used as an alternative to other topical antibiotics for the treatment 
of bacterial conjunctivitis.  
Methods 
 The studies that were obtained for this analysis were RCT’s that included patients over 
the age of 1 who were adequately diagnosed with bacterial conjunctivitis based on criteria set 
forth by the studies’ authors. The intervention that was utilized in each of these RCT’s was 
besifloxacin ophthalmic suspension 0.6%. Comparisons to this intervention included 
moxifloxaxin ophthalmic suspension 0.5%, another fluoroquinolone in the treatment of bacterial 
Desai, Besifloxacin & Bacterial Conjunctivitis 3 
 
conjunctivitis and a vehicle suspension that did not include besifloxacin.  To gather information 
on these studies, databases such as the Cochrane Database of Systematic Reviews, MEDLINE, 
and the Ovid interface were used. All articles that were chosen were selected based on their 
importance of the outcomes to patients. Inclusion criteria that were placed for the selection of the 
studies were: 1) studies that were published in 1996 or later. 2) Studies associated with POEMS. 
3) Studies published in the English language. 4) Studies that were randomized controlled trials. 
4) Studies that were not previously used in meta-analyses or systematic reviews. Searching for 
randomized controlled studies in English using the keywords “besifloxacin,” and “bacterial 
conjunctivitis” helped to selectively limit articles that were necessary and were of importance to 
the study. The studies that were finalized and chosen were: 1) Randomized, prospective, double 
masked, vehicle controlled trial comparing besifloxacin suspension 0.6% to a vehicle 
formulation without besifloxacin. 2) Multicenter, randomized, double masked, parallel group 
study comparing besifloxacin ophthalmic suspension 0.6% to moxifloxacin ophthalmic solution 
0.5%. and 3) Randomized, multicenter, double-masked, vehicle controlled study that compared 
besifloxacin ophthalmic suspension 0.6% to a vehicle suspension without besifloxacin.  
 The characteristics of all the studies that were used in this analysis are displayed in Table 
1. The three RCT’s are similar in inclusion and exclusion criteria. Interventions are also similar 
in all the trials. The number of participants in each study varies greatly, as well as the number of 
withdrawals from the trials.  
 
 
Table 1. Characteristics of Studies Included in the Systematic Review of Besifloxacin 
Ophthalmic Suspension 0.6% for the Treatment of Bacterial Conjunctivitis 
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Study Type # Pts. Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Intervention 
Karpecki, 
et.al., 
2009 
RCT, 
double 
masked 
269 1+ Minimum grade 
1 for purulent 
conjunctival 
discharge, 
minimum grade 1 
for either bulbar 
or palpebral 
conjunctival 
injection, pinhole 
visual acuity ≥ 
20/200, negative 
pregnancy test 
Hypersensitivity to 
fluroquinolones, 
besifloxacin, or 
any other 
ingredient used in 
the study, if a 
topical medication 
was used within 
48 hours before or 
during study, if 
Abx were used 
w/in 72 hrs of the 
start of study, dx 
of viral/allergic 
conjunctivitis, hx 
of iritis, corneal 
erosion syndrome, 
ulcerative keratitis 
13 Besifloxacin 
ophthalmic 
suspension 0.6% 
given 3 times 
daily for 5 days 
McDonald
,et al., 
2009 
RCT, 
double 
masked 
1161 1+ Healthy pts, 
grade 1 or more 
purulent 
discharge and 
injection, visual 
acuity of ≥ 
20/200, 
agreement to d/c 
Abx agents, 
negative 
pregnancy test 
Use of ophthalmic 
solutions, ocular 
surgery within 6 
weeks of start of 
study, 
viral/allergic 
conjunctivitis, 
ulcerative keratitis, 
corneal erosion 
syndrome, 
hypersensitivity to 
drug/drug class 
52 Besifloxacin 
ophthalmic 
suspension 0.6% 
given 3 times 
daily for 5 days 
Tepedino, 
et al., 
2009 
RCT, 
double 
masked 
957 1+ Visual acuity ≥ 
20/200, method 
of contraception 
or negative 
pregnancy test, 
discontinued use 
of contact lenses 
Use of systemic or 
topical Abx within 
72 hrs, topical soln 
within 2 hours, 
anti-inflamm. 
agent within 48 
hrs before or 
during the study, 
pregnant or 
nursing females, 
viral/allergic 
conjunctivitis, 
corneal erosion 
syndrome, 
ulcerative keratitis, 
immunocompromi
sed, 
hypersensitivity to 
drug/drug class 
26 Besifloxacin 
ophthalmic 
suspension 0.6% 
applied 3 times 
daily for 5 days 
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Outcomes that were measured were POEMS such as the resolution of bacterial 
conjunctivitis through reduced or eliminated signs or symptoms, the microbial eradication of the 
bacteria that was the cause of the disease, and the safety of the medication used in treating 
bacterial conjunctivitis. Outcomes were measured using Cochran-Mantel-Haenszel (CMH), 
Pearson X
2
 test, Fisher exact test, individual safety outcomes assessments based on grading 
scales. Karpecki, DePaolis, Hunter, White, et al used 4 point scales for ocular discharge, bulbar 
conjunctival injection, where 0= absent, 1= mild, 2= moderate, and 3=severe. The clinical 
outcomes were then counted for each patient, and an overall score was determined. In the overall 
score, 0= scores for ocular discharge and bulbar conjunctival injection are 0, 1= improvement, 
current score less than day-1 score, 2= no change from baseline score, 3= worse, current score 
greater than day-1 score. In the study done by McDonald, Protzko, Brunner, Morris, et al, the 
investigators used a scale to determine global assessment of changes in clinical signs and 
symptoms where 0= cured, 1= improved, 2= no change from pretreatment, and 3= worse. 
Investigators Tepedino, Heller, Usner and Brunner, et al also used the same 0-3 rating scale for 
clinical outcomes where 0= resolution or cure, 1=improvement, 2= no change, and 3= worse.  
 In all three RCT’s, microbial eradication was measured through microscopy. Safety was 
measured in all studies using visual acuity and biomicroscopy for lids, limbus, conjunctiva, 
cornea, anterior chamber, lens and vitreous.   
Results 
 Two RCT’s compared besifloxacin with a vehicle suspension while another RCT 
compared besifloxacin with moxifloxacin, another topical ophthalmic antibiotic in the same drug 
class. Inclusion and exclusion criteria for each of the studies was fairly similar. Each study chose 
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participants who were above the age of 1 and healthy, non pregnant patients. The participants 
also had to have a minimum grade 1 for purulent ocular discharge and a minimum grade 1 for 
bulbar or palpebral conjunctival injection along with a pinhole visual acuity of greater than 
20/200.  The study excluded participants who had a hypersensitivity to fluoroquinolones, if the 
patients had used any topical medication on the eye within 48 hours of the start of the study, if 
antibiotics were used within 72 hours of the study or if the patient had a diagnosis of viral or 
allergic conjunctivitis. Patients with a history of corneal erosion syndrome, ulcerative keratitis, 
or iritis were also excluded from the studies.  
The results of the primary outcome, the treatment of bacterial conjunctivitis were 
presented in the articles as dichotomous data. All data from the studies were analyzed with the 
intention to treat, excluding those who were excluded from the study.  
 In the investigation done by Karpecki et al, the clinical resolution of bacterial 
conjunctivitis was 43.1% and 73.3% in the control and besifloxacin groups respectively. The 
relative benefit increase (RBI) was 70.0%, and the absolute benefit increase (ABI) was 30.2%. 
The number needed to treat (NNT) was 4 patients. The difference in the control and experimental 
groups is statistically significant with the p-value less than 0.001.
3
 
 In the study done by McDonald et al, the clinical resolution of bacterial conjunctivitis 
was 84% in the moxifloxacin group, and 84.5% in the besifloxacin group. The relative benefit 
increase and absolute benefit increase was 0.60% and 0.5% respectively. The number needed to 
treat was 200 patients. All data was included in a 95% confidence interval for RBI and ABI.
4
 
 The investigation done by Tepedino et al in comparing a vehicle suspension with 
besifloxacin ophthalmic suspension 0.6% yielded a clinical resolution and microbial eradication 
Desai, Besifloxacin & Bacterial Conjunctivitis 7 
 
of bacterial conjunctivitis of 69.1% in the control group, and 84.4% in the besifloxacin group. 
The relative risk benefit and absolute benefit increase is 22% and 15.3% respectively. The 
number needed to treat was 7 patients. All data was statistically significant with a p-value of 
0.0011.
5
  Table 2 shows a summary of all three studies and the results for the clinical resolution 
of bacterial conjunctivitis in each study.  
Table 2. Clinical Resolution of Bacterial Conjunctivitis with Besifloxacin Suspension 0.6%  
Study Besifloxacin 
group 
resolution 
of illness 
Control 
group 
resolution 
of illness 
p-value Odds 
Ratio 
(95% CI) 
RBI ABI NNT 
Karpecki, 
2009 
73.3% 43.1% <0.0001 NR 70.0% 30.2% 4* 
McDonald, 
2009  
84.5% 84% NR (-5.6%-
6.75%) 
0.60% 0.5% 200* 
Tepedino, 
2009 
84.4% 69.1% 0.0011 NR 22% 15.3% 7* 
CI= Confidence Interval, RBI= Relative Benefit Increase, ABI= Absolute Benefit Increase, 
NNT= Number Needed to Treat, NR= Not Reported 
* The outcome that was measured was the clinical resolution of bacterial conjunctivitis. The 
NNT means that for every 4/200/7 patients who participated and received besifloxacin treatment, 
there was one more resolution of bacterial conjunctivitis than in the group of patients taking the 
vehicle suspension or the moxifloxacin suspension.  
 Each study also calculated the incidence of adverse effects in terms of safety of 
besifloxacin ophthalmic suspension 0.6%. In the study done by Karpecki et al, the incidence of 
adverse events for besifloxacin group was 50.4%, and was 53% for the control group. The 
relative risk increase (RRI) was -4.9%, and the absolute risk increase (ARI) was -3.0%. The 
number needed to harm is -34 patients. 
 In the study completed by McDonald et al, the incidence of ocular adverse events was 
12% in the besifloxacin group and 14% in the control group with moxifloxacin. The relative risk 
increase was -14.3% and the absolute risk increase was -2.0%. The number needed to harm was 
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-50 patients.
4
 
 Tepedino et al completed a study between a vehicle suspension and besifloxacin 
ophthalmic suspension 0.6% in which the incidence of adverse events for the besifloxacin group 
was 9.2% and the adverse events for the control group, or the vehicle suspension without 
besifloxacin was 13.9%. The relative risk increase was calculated to be 33.8% and the absolute 
risk increase was calculated as -4.7%. The number needed to harm in this study was -22 patients. 
The data in this study was statistically significant with a p-value of 0.0047. Table 3 shows a 
summary of the incidence of adverse events in patients with besifloxacin and in the control group 
for each study performed.
5
 
Table 3- Incidence of Adverse Events of Besifloxacin and Control Groups 
Study Besifloxacin 
Incidence of 
Adverse 
Events 
Control 
Group 
Incidence 
of Adverse 
Events 
p-value RRI ARI NNH 
Karpecki, 
2009 
50.4% 53% NR -4.9% -3.0% -34* 
McDonald, 
2009 
12% 14% NR -14.3% -2.0% -50* 
Tepedino, 
2009 
9.2% 13.9% 0.0047 -33.8% -4.7% -22* 
 RRI= Relative Risk Increase, ARI= Absolute Risk Increase, NNH= Number Needed to Harm, 
NR=  Not Reported 
* Since the outcome measured were adverse events in those participants receiving besifloxacin 
ophthalmic suspension 0.6%, the values mean that for every -34/-50/-22 patients treated with 
besifloxacin, there was one fewer incidence of adverse events experienced than in the group 
receiving the vehicle solution.  
 In all three studies performed with besifloxacin, the most common adverse event that was 
reported was ocular irritation. Patients reported itching of the eyes or irritation after 
administration of the medication. However, in all three studies, the incidence of adverse events 
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in the besifloxacin group were significantly lower than the incidence of adverse events in the 
control group, whether it be a vehicle suspension without besifloxacin or moxifloxacin. The most 
common adverse events that were reported in each of the studies was eye irritation, blurred 
vision and ocular pruritis.  Karpecki and associated analyzed ocular adverse events in the 
experimental and control groups. They determined that the overall ocular adverse event rate in 
the eyes that were treated with besifloxacin was 34.7%, whereas the ocular adverse event rate in 
the eyes that were treated with vehicle suspension not containing besifloxacin was 38.8%. Table 
3 displays the results of the ocular adverse events that occurred during the Karpecki et al study 
on besifloxacin.
3
 
Table 3. Incidence of Ocular Adverse Events in Besifloxacin and Vehicle Suspension Groups 
Ocular Adverse Event Besifloxacin (n=190) Vehicle (n=188) 
Eye Pain 20 (10.5%) 13 (6.9%) 
Blurred Vision 20 (10.5%) 22 (11.7%) 
Eye Irritation 14 (7.4%) 23 (12.2%) 
n= number of participants 
Discussion 
In the double masked RCT that was conducted by Karpecki and associates, the results 
displayed success for the besifloxacin intervention. The clinical resolution of bacterial 
conjunctivitis was 73.3% for the besifloxacin experimental group whereas the resolution of 
bacterial conjunctivitis was 43.1% for the vehicle suspension group. Both interventions were 
administered similarly 3 times a day for 5 days.
3
 McDonald et al determined in their double 
blinded RCT that moxifloxacin and besifloxacin were similar in efficacy due to their similar 
properties. The clinical resolution for besifloxacin and moxifloxacin was 58.3% and 59.4% 
respectively. The solutions were also used three times daily for a total of 5 days.  The study also 
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noted that the 95% Confidence Interval of the clinical resolution rates showed that besifloxacin 
was not inferior to moxifloxacin despite a difference in their success rates.
4 
 The administration 
of besifloxacin and a vehicle suspension for three times daily for five days in the Tepedino et al 
double blinded study also yielded results in favor of the besifloxacin intervention. The clinical 
resolution of bacterial conjunctivitis in the besifloxacin group and in the vehicle group without 
besifloxacin was 45.2% and 33.0% respectively.
5 
All three of the RCTs included a patient population over the age of 1. However, there is 
no information on the results of clinical resolution and adverse events of besifloxacin between 
children and adults. More information is needed on the efficacy of the medication between the 
two groups as well as the strength and the administration of the medication that can be given to 
children versus adults. This information will likely allow primary care providers to determine if 
besifloxacin is safe and effective for children also.  
Authors of the RCT also mentioned that besifloxacin, a fluoroquinolone was effective in 
eradicating the bacteria that are the most likely causes for bacterial conjunctivitis. 
Fluroquinolones cover Gram positive bacteria as well as Gram negative bacteria, and the 
efficacy of besifloxacin in the microbial resolution of the bacterial conjunctivitis is vital 
information on treating most cases of bacterial conjunctivitis.  
A limitation of each study was the comparison of clinical resolution rates between 
treating bacterial conjunctivitis symptomatically with no medication and using besifloxacin for 
treating bacterial conjunctivitis from Day 1. There is no information on how the outcome of the 
disease would have been in regards to duration of the disease if besifloxacin was not used for 
five days to treat the illness. A study comparing the duration of the disease in using besifloxacin 
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versus no medication would be helpful to determine if bacterial conjunctivitis is a disease to be 
treated with medications or not.  
Conclusions 
 The trials that were reviewed established that besifloxacin is safe and effective in treating 
bacterial conjunctivitis. Since besifloxacin suspension was only studied using one strength, 
0.6%, there was a limitation in knowing the efficacy at different strengths of the medication. 
Future studies should be designed to include different classes of drugs that can be used to treat 
bacterial conjunctivitis. The length of the administration of the medication should also vary to 
determine the recommended duration of treatment. The results of these future studies will help to 
determine the best medicinal option in the treatment of bacterial conjunctivitis.  
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